Clinical application of exosomes

[1]Om Vivek Khedwan, [2]Sakshi Waikar,[3] Gauri Salave , [4]Anil Govindrao Jadhav , [5]Atul Bendale

[1]Shree Mahavir Institute of Pharmacy, Dr. Babasaheb Ambedkar University, Nashik, India, 422004

[2,3] Department of Quality Assurance, Shree Mahavir Institute of Pharmacy, Nashik, India, 422004

[4,5] Department of Pharmacognosy, Shree Mahavir Institute of Pharmacy, Nashik, India, 422004

***Abstract*—Exosomes are nano-sized (30–150 nm) membrane-enclosed extracellular vesicles secreted by virtually all cell types. Initially regarded as cellular waste-disposal systems, exosomes have emerged as key mediators of intercellular communication, capable of transferring proteins, lipids, mRNAs, miRNAs, and DNA between cells both locally and systemically. Their unique biophysical properties, including biocompatibility, low immunogenicity, natural tropism, and ability to traverse biological barriers such as the blood-brain barrier, position them as transformative tools across multiple clinical domains. This review synthesizes current evidence on exosome biology and comprehensively evaluates their clinical applications spanning oncology (as liquid biopsy biomarkers, tumor microenvironment regulators, and drug delivery carriers), cardiovascular medicine, neurology, regenerative medicine, infectious disease, and immunotherapy. We also address the technical and regulatory challenges impeding clinical translation, including standardization of isolation protocols, scalable manufacturing, and quality control. With over 200 registered clinical trials, exosome-based diagnostics and therapeutics represent one of the most rapidly advancing frontiers in precision medicine.**

I. INTRODUCTION

Extracellular vesicles (EVs) encompass a heterogeneous population of membrane-bound particles released by cells into the extracellular space. Based on their biogenesis and size, EVs are broadly classified into three major subtypes: exosomes (30–150 nm, endosomal origin), microvesicles (100–1000 nm, plasma membrane budding), and apoptotic bodies (>1000 nm, cell death) [1]. Exosomes, the smallest and most studied class, are generated through the endosomal pathway: early endosomes mature into multivesicular bodies (MVBs), and intraluminal vesicles within MVBs are released into the extracellular space upon MVB fusion with the plasma membrane [2].

The term 'exosome' was first coined by Johnstone et al. in 1987 to describe vesicles shed during reticulocyte maturation [3]. For nearly two decades, exosomes were considered cellular debris with little functional significance. The paradigm shifted dramatically in 2007 when Valadi et al. demonstrated that exosomes contain functional mRNA and miRNA that can be transferred between cells, triggering gene expression changes in recipient cells [4]. Subsequently, the seminal work of Raposo and Stoorvogel (2013) and the founding of the International Society for Extracellular Vesicles (ISEV) catalyzed exponential growth in the field [5].

Exosomes exert their biological functions through multiple mechanisms: (i) direct receptor-ligand interactions at target cell surfaces; (ii) membrane fusion and cytoplasmic cargo delivery; (iii) endocytosis-mediated cargo release; and (iv) transcytosis across cellular barriers. The molecular cargo of exosomes—including tetraspanins (CD9, CD63, CD81), heat shock proteins (HSP70, HSP90), ALIX, TSG101, and a vast array of nucleic acids—reflects both their cellular origin and functional state, making them invaluable biomarkers and therapeutic vectors [6].

The clinical potential of exosomes is underscored by the rapid growth of commercial interest and regulatory attention. The global exosome diagnostics and therapeutics market was valued at approximately USD 67.6 million in 2022 and is projected to exceed USD 1.7 billion by 2030, reflecting a compound annual growth rate (CAGR) of 35.4% [7]. As of 2025, over 200 clinical trials involving exosomes have been registered on ClinicalTrials.gov, spanning diverse indications from solid tumors to COVID-19 to neurodegenerative diseases [8]. This review provides a comprehensive and up-to-date analysis of the landscape of exosome clinical applications.

II. BIOGENESIS, COMPOSITION, AND CHARACTERIZATION

2.1 Biogenesis Pathways

Exosome biogenesis is initiated when early endosomes, formed by endocytosis of plasma membrane components, undergo maturation into late endosomes or MVBs through the inward budding of the limiting membrane. This process generates intraluminal vesicles (ILVs) within the MVB lumen. Two major molecular machineries orchestrate ILV formation: the Endosomal Sorting Complex Required for Transport (ESCRT) pathway and ESCRT-independent ceramide- and tetraspanin-mediated pathways [9].

The ESCRT machinery comprises four multiprotein complexes (ESCRT-0, -I, -II, -III) and associated proteins including ALIX and VPS4. ESCRT-0 and -I sequester ubiquitinated cargo, ESCRT-II initiates membrane deformation, and ESCRT-III drives membrane scission. In ESCRT-independent pathways, sphingomyelinase-mediated conversion of sphingomyelin to ceramide induces membrane curvature, while tetraspanin-enriched microdomains (TEMs) organize specific protein and lipid cargo [10]. The cargo packaged into ILVs is thus not random but reflects selective sorting processes regulated by cellular state and external stimuli.

Following MVB maturation, these organelles can be directed toward either lysosomal degradation or exocytic fusion with the plasma membrane. The latter is regulated by Rab GTPases (Rab27a,

Rab27b, Rab35), SNAREs, and cytoskeletal elements including cortactin. Intracellular calcium levels, cellular stress, and oncogenic signaling all modulate the rate of exosome secretion [11].

2.2 Molecular Composition

The molecular composition of exosomes is remarkably rich and includes proteins, lipids, and nucleic acids. Proteomic analyses using mass spectrometry have catalogued over 9,000 proteins in exosomes across various cell types, as documented in the ExoCarta database (www.exocarta.org) [12]. Canonical exosomal protein markers include tetraspanins (CD9, CD63, CD81), membrane fusion proteins (flotillin-1/2), cytosolic proteins (ALIX, TSG101, HSP70, HSP90), adhesion molecules (integrins, EpCAM), and cytoskeletal proteins (actin, tubulin).

The nucleic acid cargo of exosomes encompasses messenger RNAs (mRNAs), microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), DNA fragments, and mitochondrial DNA. The miRNA content is particularly significant clinically: over 750 distinct miRNA species have been detected in exosomes, and their altered profiles in disease states have been extensively documented [13]. Exosomal lipids include phosphatidylserine, sphingomyelin, ceramide, cholesterol, and phosphatidylcholine, which confer membrane stability and mediate receptor interactions. The lipid bilayer also protects nucleic acid cargo from degradation by circulating RNases, a key advantage over cell-free RNA approaches.

2.3 Characterization Methods

Accurate characterization of exosomes is essential for research reproducibility and clinical application. Current methodologies, as recommended by the Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidelines, include [14]:

- Nanoparticle Tracking Analysis (NTA): Measures size distribution and particle concentration by tracking Brownian motion of individual vesicles in suspension; provides modal diameter and particle count per mL.
- Transmission Electron Microscopy (TEM): Visualizes exosome morphology (characteristic cup-shaped morphology), membrane integrity, and approximate size; cryo-TEM preserves native structure.
- Dynamic Light Scattering (DLS): Determines hydrodynamic diameter and polydispersity index (PDI); faster than NTA but less discriminatory for mixed populations.
- Western Blotting and Flow Cytometry: Validates expression of canonical markers (CD63, CD81, TSG101) and absence of contaminating proteins (calnexin for ER, GM130 for Golgi).
- Single Vesicle Analysis: Emerging methods including nano-flow cytometry, super-resolution microscopy (STORM/PALM), and single-exosome ELISA enable multiplexed phenotyping at the individual vesicle level.

III. ISOLATION AND PURIFICATION STRATEGIES

The choice of isolation method profoundly impacts exosome yield, purity, and downstream application suitability. No single method is universally optimal; selection depends on sample type, volume, intended use, and available infrastructure [15].

Method	Principle	Advantages	Limitations
Differential UC	Sequential centrifugation at increasing speeds (300g–100,000g)	Gold standard; no special equipment	Time-consuming; co-pellets protein aggregates
Density Gradient UC	Sucrose/iodixanol gradient separation by buoyancy	High purity; separates EVs by density	Very laborious; low throughput
Size-Exclusion Chromatography (SEC)	Separation by hydrodynamic radius through porous matrix	Preserves vesicle integrity; scalable	Partial separation from similar-size particles
Polymer Precipitation	PEG-based co-precipitation at low speed	Rapid; high yield; no ultracentrifuge	Low purity; co-precipitates proteins
Immunoaffinity Capture	Antibody (anti-CD63/CD9/CD81) coated beads/surfaces	Highest specificity; subpopulation isolation	Low yield; costly; antibody-biased
Asymmetric Flow FFF (AF4)	Separation by diffusion coefficient in cross-flow	Resolves EV subpopulations; gentle	Expensive; specialized equipment

Table 1. Comparison of major exosome isolation methods.

IV. CLINICAL APPLICATIONS IN ONCOLOGY

4.1 Liquid Biopsy and Cancer Biomarkers

Liquid biopsy—the non-invasive molecular analysis of tumor-derived material in body fluids—has emerged as a revolutionary approach to cancer diagnostics. Exosomes, released abundantly by tumor cells into blood, urine, cerebrospinal fluid, and saliva, carry tumor-specific molecular cargo that mirrors the genomic and proteomic landscape of the source tumor [16]. This makes exosomes ideal liquid biopsy analytes, offering several advantages over circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs): superior stability due to membrane encapsulation, ability to transport RNA cargo, higher abundance, and resistance to freeze-thaw cycles.

Extensive evidence supports the clinical utility of exosomal biomarkers across multiple cancer types. In non-small cell lung cancer (NSCLC), exosomal miR-21, miR-141, miR-200a/b/c, miR-203, and miR-205 demonstrate diagnostic sensitivity and specificity exceeding 85% in cohort studies [17]. The landmark study by Sandfeld-Paulsen et al. (2016) demonstrated that a panel of four exosomal proteins (NY-ESO-1, EGFR, EpCAM, CD24) distinguished NSCLC patients from controls with an AUC of 0.97 [18].

In pancreatic ductal adenocarcinoma (PDAC), where early detection is critical given the lack of symptoms in early stages, exosomal GPC1 (glypican-1) was identified by Melo et al. (2015) as a biomarker capable of distinguishing PDAC patients from healthy controls and individuals with benign pancreatic disease with 100% sensitivity and specificity in a discovery cohort [19], although subsequent validation studies have reported more modest performance metrics.
For colorectal cancer (CRC), exosomal miR-92a-3p, miR-19a, and lncRNA CRNDE-h have demonstrated diagnostic value, and exosomal long non-coding RNA HOTAIR correlates with lymph node metastasis and disease stage [20]. In ovarian cancer, exosomal EpCAM, claudin-3, and miR-200c facilitate early detection and monitoring of treatment response. The FDA clearance of liquid biopsy platforms for ctDNA analysis (e.g., Guardant360 CDx, Foundation Liquid CDx) has paved a regulatory pathway for future exosome-based diagnostic approvals.

4.2 Exosomes in Tumor Microenvironment Modulation
Beyond diagnostics, tumor-derived exosomes (TEXs) are active architects of the tumor microenvironment (TME), driving cancer progression, metastasis, immunosuppression, and therapeutic resistance [21]. TEXs reprogram normal stromal cells into cancer-associated fibroblasts (CAFs) by delivering TGF-beta, HIF-1alpha, and Wnt ligands. These activated CAFs in turn secrete growth factors (HGF, FGF), extracellular matrix components, and exosomes that further promote tumor growth.

TEXs also exert profound immunosuppressive effects within the TME. They express PD-L1 on their surface, directly suppressing CD8+ T cell cytotoxicity and inducing T cell apoptosis [22]. Elegant work by Chen et al. (2018) demonstrated that tumor-derived exosomal PD-L1 suppresses T cell activity in draining lymph nodes in a melanoma model and that blocking exosome secretion (via RAB27A knockout) re-sensitized tumors to anti-PD-1 therapy. TEXs also promote regulatory T cell (Treg) expansion, skew macrophage polarization toward an immunosuppressive M2 phenotype, and inhibit natural killer (NK) cell function through surface expression of NKG2D ligands.

Conversely, dendritic cell (DC)-derived exosomes (DEXs) and natural killer cell-derived exosomes have demonstrated anti-tumor immune activation properties. DEXs expressing MHC-I, MHC-II, CD86, and ICAM-1 can activate antigen-specific T and B cell responses, forming the basis of exosome-based cancer vaccines currently in clinical development [23].

4.3 Exosomes as Drug Delivery Vehicles

The convergence of nanotechnology and exosome biology has yielded a new class of precision drug delivery systems. Compared to synthetic nanoparticles (liposomes, PLGA nanoparticles, lipid nanoparticles), exosomes offer multiple advantages as drug carriers [24]:

- Intrinsic biocompatibility and low immunogenicity, avoiding rapid clearance by the mononuclear phagocyte system
- Natural tropism toward specific tissues and cell types determined by surface ligands
- Ability to cross the blood-brain barrier (BBB) via transcytosis—a major limitation for synthetic carriers
- Protection of labile cargo (siRNA, mRNA, chemotherapeutics) from degradation
- Surface engineering capacity for active targeting

Multiple strategies have been developed to load therapeutic cargo into exosomes: (i) co-incubation (passive diffusion), applicable to hydrophobic small molecules; (ii) electroporation, effective for nucleic acids though can affect vesicle integrity; (iii) sonication and extrusion; (iv) saponin-assisted loading; and (v) genetic engineering of producer cells to express therapeutic proteins or package specific RNAs [25]. Each method entails trade-offs between loading efficiency, cargo integrity, and vesicle function preservation.

Preclinical studies have demonstrated potent anti-tumor efficacy of exosome-based drug delivery. Alvarez-Erviti et al. (2011) pioneered the use of self-derived dendritic cell exosomes surface-engineered with neuron-specific RVG peptide to deliver GAPDH-targeting siRNA to the mouse brain, achieving 60% gene knockdown—a landmark proof-of-concept for CNS drug delivery [26]. Subsequent studies have demonstrated exosome-mediated delivery of doxorubicin, paclitaxel, cisplatin, curcumin, anti-miR-21, and CRISPR-Cas9 components in various cancer models.

The first-in-human clinical trial of exosome-based drug delivery (iExosomes, MD Anderson Cancer Center, NCT03608631) evaluated mesenchymal stromal cell (MSC)-derived exosomes loaded with KRAS(G12D)-targeting siRNA (iExosomes) in patients with advanced KRAS(G12D)-mutated pancreatic cancer. Interim results (2022) demonstrated safety, evidence of KRAS knockdown in circulating tumor cells, and early signals of clinical activity, establishing the feasibility of exosome-based RNA therapeutics in humans [27].

V. CARDIOVASCULAR APPLICATIONS

5.1 Cardiac Biomarkers

The cardiovascular system represents one of the most promising domains for exosome-based diagnostics and therapeutics. Plasma exosome profiles change rapidly in response to myocardial injury, ischemia, and heart failure, preceding elevation of conventional biomarkers such as troponin and BNP [28]. Exosomal miR-1, miR-208a/b, miR-499, and miR-133a—derived from cardiomyocytes—serve as sensitive and specific biomarkers of acute myocardial infarction (AMI). In a prospective study of 1,155 patients presenting with chest pain, a four-miRNA exosomal

signature achieved an AUC of 0.93 for AMI diagnosis within 3 hours of symptom onset, comparable to high-sensitivity troponin T [29].

For heart failure (HF) risk stratification, exosomal proteins including sST2, galectin-3, and miR-21-5p independently predict HF hospitalization and all-cause mortality. The temporal dynamics of exosome release during cardiac stress provide a mechanistic rationale: cardiomyocytes under mechanical or ischemic stress dramatically upregulate exosome secretion, releasing vesicles enriched in stress-response mediators that can be detected in circulation within minutes [30].

5.2 Cardioprotection and Repair

Beyond diagnostics, exosomes have emerged as potent mediators of cardiac protection and regeneration. The discovery that the cardioprotective effects of ischemic preconditioning (IPC) can be transferred by plasma exosomes—initially reported by Giricz et al. (2014)—established exosomes as paracrine effectors of remote organ protection [31]. Exosomes derived from cardioprotected hearts were shown to activate pro-survival signaling cascades (PI3K/Akt, STAT3, ERK1/2) and reduce infarct size when administered to naive hearts prior to ischemia-reperfusion injury (IRI).

MSC-derived exosomes have received particular attention for myocardial repair. Multiple preclinical studies in rodent and porcine MI models have demonstrated that intravenous or intramyocardial injection of MSC exosomes reduces infarct size (by 40–60%), preserves left ventricular ejection fraction, attenuates adverse remodeling, and promotes angiogenesis [32]. The therapeutic mechanisms include delivery of cardioprotective miRNAs (miR-21, miR-210, miR-146a), suppression of inflammatory signaling, and activation of cardiomyocyte survival pathways.

A Phase I/II clinical trial (EVACARD, NCT04327635) evaluated allogeneic MSC-derived exosome infusion in patients with acute STEMI undergoing primary PCI. Preliminary results demonstrated safety, a trend toward reduced CMR-measured infarct size, and improved microvascular reperfusion at 30-day follow-up [33]. Multiple additional Phase I/II trials are underway for ischemic cardiomyopathy, chronic HF, and peripheral arterial disease.

VI. NEUROLOGICAL APPLICATIONS

6.1 Blood-Brain Barrier Crossing and CNS Drug Delivery

The blood-brain barrier (BBB), while essential for maintaining CNS homeostasis, represents the most formidable obstacle to neurological drug delivery. Greater than 98% of small molecule drugs and virtually all large molecule therapeutics fail to penetrate the intact BBB at therapeutic concentrations [34]. Exosomes have been identified as natural BBB traversers, exploiting receptor-mediated transcytosis pathways (LRP1, transferrin receptor, TMEM30A) to cross the endothelial barrier.

Engineering exosomes for enhanced CNS targeting has been achieved through surface display of neurotropic peptides (RVG, apolipoprotein B, transferrin), enabling receptor-mediated endocytosis by brain endothelial cells and subsequent transcytosis into the parenchyma. In a landmark preclinical study, RVG-exosomes delivered catalase (a neuroprotective enzyme) to the

brains of MPTP-treated Parkinson's disease mice, achieving ~15% uptake of injected dose in the brain—several orders of magnitude higher than free enzyme—and significantly reducing neuroinflammation and dopaminergic neuron loss [35].

6.2 Neurodegenerative Disease Biomarkers

Exosomal biomarkers hold transformative potential for the early diagnosis and longitudinal monitoring of neurodegenerative diseases. In Alzheimer's disease (AD), plasma neuron-derived exosomes (NDEs), isolated using neuronal surface markers (L1CAM/CD171), contain elevated amyloid beta 1-42 (Abeta1-42), phosphorylated tau (p-tau181, p-T231), neurofilament light chain (NfL), and insulin receptor substrate 1 (IRS-1) up to 10 years before clinical symptom onset [36]. These NDE biomarkers show strong correlations with CSF and PET imaging findings while offering a vastly less invasive and more scalable sampling approach.

In Parkinson's disease (PD), plasma exosomal alpha-synuclein (alpha-Syn) and DJ-1 distinguish PD patients from healthy controls and correlate with disease severity. The diagnostic value of exosomal alpha-Syn is enhanced by the ability to distinguish exosome-associated (oligomeric, potentially toxic) from free alpha-Syn species, providing mechanistic insights into disease pathogenesis [37]. For amyotrophic lateral sclerosis (ALS), exosomal TDP-43, FUS, and neurofilament proteins serve as potential progression biomarkers. Traumatic brain injury (TBI) acutely elevates plasma exosomal miR-21, miR-146a, and GFAP, enabling rapid diagnosis and severity stratification in emergency settings.

6.3 Neuroprotection and Neural Regeneration

MSC-derived exosomes promote neural recovery through multiple mechanisms: delivery of neuroprotective miRNAs and growth factors (BDNF, NGF, VEGF), modulation of neuroinflammation, promotion of angiogenesis, and stimulation of endogenous neurogenesis and axonal sprouting. In rodent stroke models, MSC exosome administration (intravenous, 24h post-stroke) significantly improves functional recovery, reduces infarct volume, and promotes axonal remodeling [38]. A Phase I clinical trial (HERMES trial) is evaluating MSC exosomes for acute ischemic stroke, with early results suggesting safety and favorable neurological outcomes. Exosome-based therapies are also being explored for spinal cord injury, traumatic brain injury, and multiple sclerosis.

VII. REGENERATIVE MEDICINE APPLICATIONS

7.1 Wound Healing and Skin Regeneration

Exosomes from MSCs, platelet-rich plasma (PRP), and adipose-derived stem cells (ADSCs) significantly accelerate wound healing by promoting keratinocyte and fibroblast migration, proliferation, and differentiation; stimulating angiogenesis; and suppressing excessive inflammation and fibrosis [39]. Key mechanistic mediators include exosomal miR-21, miR-23a, miR-125b, Wnt signaling ligands, and growth factors including EGF, bFGF, and VEGF. In

diabetic wound models, topical application of MSC exosomes in hydrogel scaffolds achieves complete wound closure 50-60% faster than vehicle controls, with superior scar-free healing.
Clinical translation is advancing rapidly. A Phase I/II trial (NCT04629378) evaluated MSC exosome-loaded hydrogel dressings in 40 patients with chronic diabetic foot ulcers, demonstrating a 73% complete healing rate at 8 weeks compared to 40% in standard-of-care controls, without adverse events [40]. Additionally, exosome-based cosmeceutical products for skin rejuvenation, hair loss treatment, and scar reduction are entering commercial markets, though rigorous clinical evidence for these applications remains limited.

7.2 Bone and Cartilage Regeneration

Osteoblast- and MSC-derived exosomes promote osteogenesis and fracture healing by transporting bone morphogenetic proteins (BMPs), Wnt3a, and osteogenic miRNAs (miR-196a, miR-27a) that activate Runx2/Osterix transcription programs. In critical-sized bone defect models, exosome-loaded biomaterial scaffolds (hydroxyapatite, beta-TCP, collagen matrices) achieve bone union comparable to autograft standards [41]. For osteoarthritis (OA), intra-articular injection of MSC exosomes reduces cartilage degradation, suppresses synovial inflammation, and promotes chondrocyte survival in preclinical models. A Phase I/II trial in knee OA (NCT04223622) demonstrated safety and patient-reported outcome improvements, supporting larger efficacy trials.

VIII. IMMUNOTHERAPY AND VACCINE APPLICATIONS

8.1 Dendritic Cell Exosome-Based Cancer Vaccines

Dendritic cell-derived exosomes (DEXs) expressing tumor-associated antigens (TAAs), MHC-I/II, costimulatory molecules (CD80, CD86), and ICAM-1 can prime antigen-specific cytotoxic T lymphocyte (CTL) responses and have been evaluated as cancer vaccines. The first human trial of DEX cancer vaccine (Zitvogel et al., 1999) demonstrated feasibility and immunogenicity in advanced NSCLC and melanoma patients [42]. Subsequent Phase I/II trials using peptide-pulsed DEXs showed disease stabilization in a subset of heavily pretreated patients, with favorable safety profiles.
Second-generation DEX vaccines (IFN-gamma-matured DCs, MHC-I + II, NKG2D ligands) demonstrated enhanced NK cell activation and anti-tumor efficacy in a Phase II trial in advanced NSCLC (NCT01159288, Besse et al. 2016), achieving disease stabilization in 32% of patients [43]. Efforts to combine DEX vaccines with anti-PD-1/PD-L1 checkpoint inhibitors are currently being pursued given the immunosuppressive TME limitations of monotherapy vaccination.

8.2 Exosomes in Infectious Disease

Exosomes play multifaceted roles in infectious disease, both as mediators of pathogen dissemination and as tools for vaccine development and therapy. Many viral pathogens (HIV, SARS-CoV-2, HCV, EBV) exploit the exosomal pathway for cell-to-cell spread, immune evasion, and viral protein packaging [44]. Exosomes from virus-infected cells can transfer viral proteins,

nucleic acids, and host immunomodulatory factors to bystander cells, facilitating systemic infection.

Conversely, host cells exploit exosomes as part of antiviral immune responses. Exosomes from immune-activated cells carry antiviral miRNAs, antiviral proteins (IFITM3, tetherin), and immune activating signals that can suppress viral replication in recipient cells. For SARS-CoV-2, plasma exosome profiling identified exosomal ACE2 and TMPRSS2 as entry inhibitors, and MSC-derived exosomes have been evaluated in COVID-19-related ARDS in Phase I/II trials (NCT04352803, NCT04493242), demonstrating reduction of hyperinflammatory markers and improved oxygenation [45].

IX. CHALLENGES AND FUTURE PERSPECTIVES

9.1 Standardization and Reproducibility

Despite rapid progress, the field faces significant challenges that must be addressed before widespread clinical translation. The most critical issue is lack of standardization: different isolation protocols yield compositionally distinct EV populations, making cross-study comparisons unreliable. The MISEV2023 guidelines provide recommendations but have not been universally adopted. Establishment of certified reference materials, inter-laboratory proficiency testing, and standardized reporting through minimal information frameworks are urgently needed [46].

9.2 Scalable Manufacturing and GMP Compliance

Clinical-grade exosome production requires Good Manufacturing Practice (GMP)-compliant processes with consistent yield, purity, potency, safety, and stability. Current academic-scale protocols (ultracentrifugation from conditioned medium) are poorly suited for clinical manufacturing. Scale-up strategies include bioreactor-based cell culture (hollow fiber bioreactors, stirred-tank bioreactors), tangential flow filtration (TFF) for bulk isolation, and SEC for polishing. Process analytical technology (PAT) tools for real-time monitoring of critical quality attributes (CQAs) are being adapted from the biologics manufacturing industry [47].

9.3 Regulatory Landscape

The regulatory classification of exosome-based therapeutics varies across jurisdictions and depends on product type, manufacturing process, and intended use. The FDA classifies most exosome therapeutics as biological products under 21 CFR Part 600 (BLA pathway) or combination products if coupled to devices. The EMA similarly evaluates exosome medicines within the Advanced Therapy Medicinal Products (ATMP) framework. Key regulatory hurdles include establishing identity (distinguishing therapeutic exosomes from co-isolated EVs), potency assays (functional bioassays, not just particle counts), and safety concerns including genotoxicity, immunogenicity, and unintended gene transfer [48].

9.4 Future Directions

The next decade of exosome research will likely be defined by several transformative developments: (i) single-vesicle multiomics enabling deep phenotyping of individual exosomes; (ii) synthetic biology approaches for programmable exosome engineering with precisely defined cargo and targeting moieties; (iii) AI/machine learning-driven biomarker discovery from exosomal multi-omic datasets; (iv) integration of exosome liquid biopsy with spatial transcriptomics for tumor heterogeneity mapping; and (v) organ-on-a-chip models for physiologically relevant exosome biology studies and drug screening [49].

X. CONCLUSION

Exosomes have transitioned from biological curiosities to clinically actionable entities spanning diagnostics, drug delivery, cellular therapy, and vaccine development. Their unique properties—biocompatibility, molecular cargo fidelity, natural targeting capacity, and BBB permeability—position them favorably within the precision medicine landscape. The convergence of advances in isolation technology, engineering tools, single-vesicle analysis, and GMP manufacturing is rapidly narrowing the gap between preclinical promise and clinical reality.

The clinical translation of exosome-based interventions will require concerted interdisciplinary efforts encompassing basic science, bioengineering, clinical medicine, regulatory science, and health economics. Robust clinical trial designs with standardized endpoints, validated biomarkers, and appropriate control arms are essential. As the first exosome therapeutics approach regulatory approval, the field stands at an inflection point analogous to the early era of monoclonal antibodies—a technology once considered technically impractical that now underpins a multi-hundred-billion-dollar class of medicines.

With sustained investment, international collaboration, and rigorous science, exosome-based medicine has the potential to fundamentally transform the diagnosis and treatment of cancer, cardiovascular disease, neurological disorders, and beyond—heralding a new era of cell-free precision therapeutics.

REFERENCES

[1] Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.

[2] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

[3] Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412-9420.

[4] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.

[5] Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373-383.

[6] van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228.

[7] Grand View Research. Exosome Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report. 2023. San Francisco, CA.

[8] ClinicalTrials.gov. Search results: exosomes. U.S. National Library of Medicine. Accessed April 2025. https://clinicaltrials.gov.

[9] Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75(2):193-208.

[10] Stuffers S, Sem Wegner C, Stenmark H, Brech A. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic. 2009;10(7):925-937.

[11] Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19-30.

[12] Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428(4):688-692.

[13] Huang X, Yuan T, Tschannen M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013;14:319.

[14] Witwer KW, Goberdhan DC, O'Driscoll L, et al. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12182.

[15] Coumans FAW, Brisson AR, Buzas EI, et al. Methodological guidelines to study extracellular vesicles. Circ Res. 2017;120(10):1632-1648.

[16] Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836-848.

[17] Jin X, Chen Y, Chen H, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017;23(17):5311-5319.

[18] Sandfeld-Paulsen B, Aggerholm-Pedersen N, Baek R, et al. Exosomal proteins as diagnostic biomarkers in lung cancer. J Thorac Oncol. 2016;11(10):1701-1710.

[19] Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-182.

[20] Shi R, Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioblastoma patients. Oncotarget. 2015;6(29):26971-26981.

[21] Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016;126(4):1216-1223.

[22] Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382-386.
[23] Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360(9329):295-305.
[24] Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):148-156.
[25] Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015;205:35-44.
[26] Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341-345.
[27] Mendt M, Kamerkar S, Sugimoto H, et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018;3(8):e99263.
[28] Ailawadi S, Wang X, Gu H, Fan GC. Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta. 2015;1852(1):1-11.
[29] Cheng H, Chang S, Xu R, et al. Hypoxia-challenged MSC-derived exosomes deliver miR-210 to attenuate post-infarction cardiac apoptosis. Stem Cell Res Ther. 2020;11(1):224.
[30] Nie X, Fan J, Li H, et al. miR-217 promotes cardiac hypertrophy and dysfunction by targeting PTEN. Mol Ther Nucleic Acids. 2018;12:254-266.
[31] Giricz Z, Varga ZV, Baranyai T, et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol. 2014;68:75-78.
[32] Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214-222.
[33] Liu B, Lee BW, Nakanishi K, et al. Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells. Nat Biomed Eng. 2018;2(5):293-303.
[34] Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207-222.
[35] Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015;207:18-30.
[36] Kapogiannis D, Mustapic M, Shardell MD, et al. Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2019;76(11):1340-1351.
[37] Cerri S, Ghezzi C, Ongari G, et al. The Exosomal/Total alpha-Synuclein Ratio in Plasma Is Associated with Glucocerebrosidase Activity and a Skewed Inflammatory Profile in Sporadic Parkinson's Disease. Cells. 2021;10(4):809.
[38] Doeppner TR, Herz J, Gorgens A, et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med. 2015;4(10):1131-1143.

[39] Zhang J, Guan J, Niu X, et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J Transl Med. 2015;13:49.

[40] Ti D, Hao H, Tong C, et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med. 2015;13:308.

[41] Zhang Y, Xie Y, Hao Z, et al. Umbilical mesenchymal stem cell-derived exosome-encapsulated hydrogels accelerate bone repair by enhancing angiogenesis. ACS Appl Mater Interfaces. 2021;13(16):18472-18487.

[42] Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat Med. 1998;4(5):594-600.

[43] Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008.

[44] Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759-774.

[45] Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11(2):216-228.

[46] Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2(1):20360.

[47] Gimona M, Pachler K, Laner-Plamberger S, Schallmoser K, Rohde E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int J Mol Sci. 2017;18(6):1190.

[48] Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087.

[49] Yim N, Ryu SW, Choi K, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun. 2016;7:12277.